First proteasome inhibitor in clinical development profiled at oncology meeting May 20, 1999 No Comments
Favorable pharmacokinetic, safety and efficacy profile for FMdC in phase I; phase II trials begin May 20, 1999 No Comments
Inhibitors of Ras prenylation with bicyclic structure designed at Merck & Co. May 20, 1999 No Comments
Cell Therapeutics initiates phase II trial of Apra; phase I results presented at ASCO May 20, 1999 No Comments
RSR-13, an allosteric hemoglobin modifier, evaluated in GBM in combination with cranial radiotherapy May 19, 1999 No Comments
Potent, water-soluble paclitaxel analogue in early clinical trials presented by BMS at ASCO meeting May 19, 1999 No Comments
RSS